Dipexium Pharmaceuticals CEO Natasha Giordano's 2019 pay jumps 162% to $1.6M

Dipexium Pharmaceuticals reports 2019 executive compensation

By ExecPay News

Published: September 25, 2020

Dipexium Pharmaceuticals reported fiscal year 2019 executive compensation information on September 25, 2020.
In 2019, four executives at Dipexium Pharmaceuticals received on average a compensation package of $1M, a 129% increase compared to previous year.
Average pay of disclosed executives at Dipexium Pharmaceuticals
Natasha Giordano, Chief Executive Officer, received $1.6M in total, which increased by 162% compared to 2018. 53.59% of Giordano's compensation, or $865.8K, was in option awards. Giordano also received $265K in non-equity incentive plan, $468.8K in salary, as well as $16K in other compensation.
Rita M. O'Connor, Chief Financial Officer, received a compensation package of $1.1M, which increased by 129% compared to previous year. 47.78% of the compensation package, or $505.8K, was in option awards.
Efthymios Deliargyris, Chief Medical Officer, earned $801.7K in 2019, a 85% increase compared to previous year.
Michael J. Valentino, Chairman, received $680.3K in 2019, which increases by 127% compared to 2018.

Related executives

Michael Valentino

Dipexium Pharmaceuticals

Chairman

Natasha Giordano

Dipexium Pharmaceuticals

Chief Executive Officer

Rita O'Connor

Dipexium Pharmaceuticals

Chief Financial Officer

Efthymios Deliargyris

Dipexium Pharmaceuticals

Chief Medical Officer

You may also like

Source: SEC filing on September 25, 2020.